News about "obesity treatment "

UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment

The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.

Obesity Treatment | 15/04/2026 | By News Bureau

Hoth Therapeutics Reports Positive HT-VA CRADA Data

Hoth Therapeutics reports positive HT-VA data showing GDNF improves liver fat metabolism, reduces fat production and may outperform semaglutide in MAFLD and obesity.

Obesity Treatment | 14/04/2026 | By News Bureau

MetaVia Advances Obesity Drug Development with First Patient Dosed in DA-1726 Phase I Trial

MetaVia initiates Part 3 of its phase I trial for DA-1726, evaluating higher-dose strategies to enhance weight loss, metabolic outcomes and tolerability in obesity and cardiometabolic disease treatment.

Obesity Treatment | 13/04/2026 | By News Bureau

Emcure Slashes Price of Semaglutide-Based Weight Loss Drug Poviztra in India

Emcure reduces the price of its semaglutide-based drug Poviztra, aiming to make effective weight management treatment more accessible to patients across India.

Obesity Treatment | 04/04/2026 | By News Bureau

UK MHRA Approves up to 7.2 mg Dose of Semaglutide for Obesity Treatment

The UK MHRA has approved a higher dose of semaglutide of up to 7.2 mg for weight management in adult patients with obesity. The regimen involves three 2.4 mg injections and is indicated for use alongside a reduced-calorie diet and increased physical activity in adults with a Body Mass Index (BMI) of 30 kg/m² or higher.

Obesity Treatment | 17/01/2026 | By News Bureau |  122

Novo Nordisk Introduces Wegovy Pill with knownwell as NovoCare Provider

Novo Nordisk has launched Wegovy in an oral pill form, marking the first FDA-approved oral GLP-1 therapy, with knownwell recognised as a NovoCare provider to support broader patient access to clinician-led metabolic care across the US.

Obesity Treatment | 06/01/2026 | By News Bureau |  103

Ascletis Receives FDA IND Clearance for Phase II ASC30 Diabetes Study

Ascletis has received US FDA IND clearance to initiate a 13-week phase-II, randomised, double-blind, placebo-controlled, multi-centre study evaluating the efficacy, safety and tolerability of its oral small-molecule GLP-1 candidate ASC30 in participants with diabetes, with enrollment expected to begin in the first quarter of 2026.

Obesity Treatment | 05/01/2026 | By News Bureau |  107

Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for Novel GLP-1 Receptor Agonist

Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.

Obesity Treatment | 30/12/2025 | By News Bureau |  134

Novo Nordisk Seeks FDA Approval for CagriSema Weight-Loss Therapy

CagriSema 2.4 mg/2.4 mg is an investigational once-weekly injectable combining cagrilintide and semaglutide to target complementary obesity pathways. In the REDEFINE 1 phase III trial, patients with obesity or overweight achieved an average weight loss of 23 percent, reinforcing the company’s ongoing focus on innovation in obesity treatment.

Obesity Treatment | 19/12/2025 | By News Bureau |  182

Superluminal and Eli Lilly Partner on Next-Gen Cardiometabolic and Obesity Treatments

Superluminal Medicines has announced a collaboration with Eli Lilly and Company to advance small molecule therapeutics for cardiometabolic diseases and obesity.

Obesity Treatment | 16/08/2025 | By Dineshwori |  201